ID   RMG-II
AC   CVCL_2803
SY   RMG2; RMG-2
DR   BTO; BTO:0004929
DR   BioSample; SAMN03470819
DR   cancercelllines; CVCL_2803
DR   CGH-DB; 335-2
DR   CGH-DB; 9363-4
DR   Cosmic; 1152557
DR   Cosmic; 2582801
DR   GEO; GSM1176284
DR   JCRB; IFO50316
DR   JCRB; JCRB0172.1
DR   JCRB; FDSC0028
DR   Progenetix; CVCL_2803
DR   Wikidata; Q54950667
RX   PubMed=1715339;
RX   PubMed=11330945;
RX   PubMed=12417041;
RX   PubMed=17671176;
RX   PubMed=24023729;
RX   PubMed=25846456;
RX   PubMed=25960936;
CC   Population: Japanese.
CC   Doubling time: ~58 hours (PubMed=1715339); 84 hours (Note=Lot 07132004), ~51 hours (Note=Lot 02032016) (JCRB=JCRB0172.1).
CC   HLA typing: A*02:07,02:07; B*35:01,35:01; C*03:03,03:03; DQB1*02:02,02:02 (PubMed=25960936).
CC   Discontinued: JCRB; IFO50316; true.
CC   Discontinued: JCRB; FDSC0028; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): JCRB=JCRB0172.1
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 14
ST   D16S539: 10,12
ST   D5S818: 11
ST   D7S820: 10,12
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 23
//
RX   PubMed=1715339; DOI=10.1111/j.1349-7006.1991.tb02713.x; PMCID=PMC5918546;
RA   Nozawa S., Yajima M., Sasaki H., Tsukazaki K., Aoki D., Sakayori M.,
RA   Udagawa Y., Kobayashi T., Sato I., Furusako S., Mochizuki H.;
RT   "A new CA125-like antigen (CA602) recognized by two monoclonal
RT   antibodies against a newly established ovarian clear cell carcinoma
RT   cell line (RMG-II).";
RL   Jpn. J. Cancer Res. 82:854-861(1991).
//
RX   PubMed=11330945; DOI=10.1006/gyno.2001.6132;
RA   Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M.,
RA   Sato A., Inazawa J.;
RT   "A novel amplification at 17q21-23 in ovarian cancer cell lines
RT   detected by comparative genomic hybridization.";
RL   Gynecol. Oncol. 81:172-177(2001).
//
RX   PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x; PMCID=PMC5926887;
RA   Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M.,
RA   Takayama M., Sato A., Inazawa J.;
RT   "Differentially regulated genes as putative targets of amplifications
RT   at 20q in ovarian cancers.";
RL   Jpn. J. Cancer Res. 93:1114-1122(2002).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//